These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
322 related items for PubMed ID: 21767697
1. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C]. Burgueño-Montañés C, Pérez-Álvarez R. Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697 [Abstract] [Full Text] [Related]
2. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes? Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A. J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644 [Abstract] [Full Text] [Related]
3. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis. Ann Intern Med; 2013 Dec 03; 159(11):I-14. PubMed ID: 24297207 [No Abstract] [Full Text] [Related]
4. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C. Adams S, Ostermeier M. Optometry; 2010 Nov 03; 81(11):580-6. PubMed ID: 20655283 [Abstract] [Full Text] [Related]
8. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C]. Abellán Galiana P, Pérez-Lázaro A, Aguilera Sancho-Tello V, Merino Torres JF, Berenguer Haym M, Piñón Sellés F. Endocrinol Nutr; 2009 Mar 03; 56(3):136-9. PubMed ID: 19627727 [Abstract] [Full Text] [Related]
9. [Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin]. Iferkhass S, Elasri F, Chatioui S, Khoyaali A, Bargach T, Reda K, Oubaaz A. J Fr Ophtalmol; 2015 Jan 03; 38(1):34-40. PubMed ID: 25533994 [Abstract] [Full Text] [Related]
13. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group. J Gastroenterol Hepatol; 2012 Jul 03; 27(7):1233-40. PubMed ID: 22098185 [Abstract] [Full Text] [Related]
16. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply. Hu CC, Chien RN. Aliment Pharmacol Ther; 2013 Feb 03; 37(4):492. PubMed ID: 23336679 [No Abstract] [Full Text] [Related]
17. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them]. Iwasaki Y, Ikeda F, Yamamoto K. Nihon Rinsho; 2011 May 03; 69 Suppl 4():215-20. PubMed ID: 22096922 [No Abstract] [Full Text] [Related]
18. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV. Slim J, Afridi MS. Infect Dis Clin North Am; 2012 Dec 03; 26(4):917-29. PubMed ID: 23083824 [Abstract] [Full Text] [Related]
19. Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin. Novelli FJ, Przysiezny A, Rosa EL, Garcia RF, Nóbrega MJ. Arq Bras Oftalmol; 2014 Dec 03; 77(3):178-81. PubMed ID: 25295906 [Abstract] [Full Text] [Related]